Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Schering GMP work plan

This article was originally published in The Tan Sheet

Executive Summary

FDA has signed off on Schering-Plough's GMP work plan created as part of firm's 2002 consent decree. Schering noted in an 18-K filed with SEC June 3 that FDA concurred with the GMP compliance work plan May 14. The plan was submitted last year following a consent decree requiring Schering "to develop and submit for FDA's concurrence comprehensive cGMP work plans for the company's manufacturing facilities in New Jersey and Puerto Rico." Work plan details "significant steps" the firm must take to avoid fines under the consent decree. If Schering significantly misses a deadline, it may be forced to halt production of a drug. Under the decree, firm agreed to cease manufacturing of more than a dozen OTC drug SKUs (2"The Tan Sheet" May 27, 2002, p. 12). Schering also is under criminal investigation by Boston U.S. Attorney's Office for off-label promotion and other marketing practices relating to Rx drugs, firm said May 30...

You may also be interested in...

Schering Consumer Health Care VP-R&D O’Mullane Brings Switch Experience

Schering-Plough Consumer Health Care VP-Research & Development John O'Mullane, PhD, brings a background in Rx-to-OTC switches to his new job

Schering NDAs Not Subject To Extra Scrutiny Under FDA Consent Decree

Schering-Plough's pending supplemental NDAs to switch Claritin (loratadine) OTC appear to be unaffected by the company's GMP consent decree with FDA

Crunch Time For Protection Of New Therapeutic Uses In Europe

The pharmaceutical industry will be watching carefully as the EU Court of Justice deliberates on whether to deny or widen the granting of supplementary protection certificates on new therapeutic indications of authorized medicines.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts